N6-methyladenosine is downregulated in human atherosclerotic lesions

How does NEIL3 deficiency and RNA modifications affect atherosclerosis? Ana M. T. Quiles-Jiménez‘ PhD thesis gives some answers.


MAIN RESULTS:

  1. The RNA modification N6-methyladenosine is downregulated in human atherosclerotic lesions.
  2. The canonical DNA glycosylase NEIL3 could be a new player in atherosclerosis.

THESIS DEFENCE:

Thesis: Molecular mechanisms of atherosclerotic disease. Studies on the role of the DNA glycosylase NEIL3 and the epitranscriptome in the development of atherosclerosis
Candidate: Ana M. T. Quiles-Jiménez
Time: November 18, 2020 at 11:15
Place: Online-based solution, due to the covid-19 situation
Link to university website


SUMMARY:

(1) In atherosclerosis, levels of methyltransferases (‘writers’), binding proteins (‘readers’) and demethylases (‘erasers’) involved in methylations occurring in rRNA and mRNA are altered. The changes are accompanied by a marked downregulation of the well-known RNA modification N6-methyladenosine.

(2) NEIL3 affects vascular smooth muscle cells phenotypic identity, and could be a new player in atherosclerosis. Vascular smooth muscle cells accumulate DNA damage, which can promote plaque instability and lead to rupture and acute coronary heart disease. NEIL3 repairs damaged DNA.


REFERENCES:

(1) Quiles-Jiménez, A., Gregersen, I., de Sousa, M. M. L., Abbas, A., Kong, X. Y., Alseth, I., Alseth, I., Holm, S., Dahl, T. B:, Skagen, K., Skjelland, M., Aukrust, P., Bjørås, M., & Halvorsen, B. (2020). N6-methyladenosine in RNA of atherosclerotic plaques: An epitranscriptomic signature of human carotid atherosclerosis. Biochemical and Biophysical Research Communications.

Norheart uses cookies for analytical purposes, content and ads customisation, and to further develop our services.
Accept
Learn more
Show again